Showcasing Clinical Performance of Vedotin ADCs Sigvotatug Vedotin & PDLIV in Lung Cancer
- Spotlighting clinical data from Sigvotatug vedotin and PDL1V programs as monotherapy and in combination with pembrolizumab, highlighting the significance of vedotin ADCs causing immunogenic cell death
- Delving into the rationale and combinatorial potential of vedotin ADCs and pembrolizumab
- Laying out potential for Sigvotatug vedotin and PDLIV to improve outcomes for patients with lung cancer